Stefano Manduca

Real-world feasibility and effectiveness of a personalized exercise program during cancer treatment: results from the CHOiCE prospective study

Alice Avancini, Anita Borsati, Gloria Adamoli, Linda Toniolo et autres

BACKGROUND: Despite strong evidence supporting exercise in oncology, real-world data on its feasibility and effectiveness across cancer types remain limited. The CHOiCE (Choose Health: Oncological patients Centered Exercise) study aimed to evaluate a flexible, patient-centered exercise program in routine clinical practice. MATERIALS …

it (code pays fourni par la source)

Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis

Francesca Zacchi, Sara Merler, Ilaria Zampiva, Irene Torresan et autres

BACKGROUND AND OBJECTIVE: Interleukin-8 (IL-8) is a chemokine involved in inflammation and primary immune response, playing a key role in recruiting neutrophils. IL-8 is produced by several cell types, including immune cells and certain cancer cells. Elevated levels of IL-8 have been …

it, my (code pays fourni par la source)

851 PBRM1/BAP1 and Interleukin-8 (IL-8) Status Complement Clinical Factors to Predict Prognosis in Metastatic Renal Cell Carcinoma (mRCC)

Stefano Manduca, Michela Piacentini, Ilaria Zampiva, Emanuela Fantinel et autres

Implementing precision oncology in renal cell carcinoma (RCC): Prospective identification of clinical, tissue-based, and circulating factors to refine outcome prediction and support therapeutic choices (SIGNS-RCC TRIAL).

Ilaria Zampiva, Emanuela Fantinel, Veronica Mollica, Sara Elena Rebuzzi et autres

TPS617 Background: At diagnosis, 55% of RCC are localized, and 25% are locally advanced/metastatic (aRCC); an additional 30% develop metastases during follow-up. Prognosis is highly variable in both resectable and advanced disease. All patients’ stratification tools are based on clinical risk scores. …

it (code pays fourni par la source)

P204 Prognosis prediction in metastatic RCC (mRCC): Integration of additional clinical factors and tissue-based classifiers to improve risk group classification accuracy

I. Zampiva, Stefano Manduca, Fossile Emanuela, Veronica Mollica et autres

096 Gene expression analysis suggests potential pathways influencing Merkel cell carcinoma outcomes

Shan Chi Yu, Shayan Cheraghlou, Marianna Babadzhanov, Nicole Adell Doudican et autres

us (code pays fourni par la source)

Additional biological and clinical characteristics to refine International Metastatic RCC Database Consortium (IMDC) prognostic/predictive assessment in metastatic renal cell carcinoma (mRCC).

Ilaria Zampiva, Sara Merler, Nicola Inzerilli, Francesca Zacchi et autres

705 Background: mRCC prognostic stratification is currently based on the IMDC score. However, some patients experience outcomes markedly different from those predicted by the median outcome of their risk class. Moreover, risk scores are prognostic, rather than predictive, and developing reproducible, affordable, …

it (code pays fourni par la source)

Remarkable response to gemcitabine rechallenge in advanced urothelial carcinoma: a case report

Sara Merler, Sarah Pafumi, Ilaria Zampiva, Francesca Zacchi et autres

Therapeutic alternatives in advanced urothelial carcinoma are limited, especially in advanced lines, with only a few drugs having demonstrated relevant clinical benefit. This article discusses about a young patient with significant cardiovascular comorbidities, already treated with recommended first- and second-line drugs, and …

it, gb (code pays fourni par la source)

1683P Implementing next generation sequencing (NGS)/molecular tumor board (MTB)-based precision oncology practice: One-year experience at the Verona University Hospital

S.T. Riva, Claudio Luchini, Francesca Zacchi, Andrea Mafficini et autres

it (code pays fourni par la source)